Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation

Boyton, India; Valenzuela, Stella M.; Collins-Praino, Lyndsey E.; Care, Andrew

doi:10.1016/j.bbi.2023.11.004

Cited by 6 publications

(2 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuronanomedicine aims to engineer nanoparticle-based drug delivery systems (NDDSs) for the targeted treatment of brain-related diseases. [1] NDDSs can enhance therapeutic efficacy while reducing side effects by improving drug stability, safety, bioavailability, and mediating drug transport across the blood-brain barrier (BBB) to specific target sites in the brain. [1] Despite such promise, however, the translation of neuronanomedicines into the clinic has been met with limited success.…”

Section: Introductionmentioning

confidence: 99%

“…[1] NDDSs can enhance therapeutic efficacy while reducing side effects by improving drug stability, safety, bioavailability, and mediating drug transport across the blood-brain barrier (BBB) to specific target sites in the brain. [1] Despite such promise, however, the translation of neuronanomedicines into the clinic has been met with limited success. This can be attributed to a poor understanding of how nanoparticles interact with complex biological systems, including the brain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Morshed,

Rennie,

Faria

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Neuronanomedicine harnesses nanoparticle technology for the treatment of neurological disorders. An unavoidable consequence of nanoparticle delivery to biological systems is the formation of a protein corona on the nanoparticle surface. Despite the well-established influence of the protein corona on nanoparticle behavior and fate, as well as FDA approval of neuro-targeted nanotherapeutics, the effect of a physiologically relevant protein corona on nanoparticle-brain cell interactions is insufficiently explored. Indeed, less than 1% of protein corona studies have investigated protein coronas formed in cerebrospinal fluid (CSF), the fluid surrounding the brain. Herein, we utilize two clinically relevant polymeric nanoparticles (PLGA and PLGA-PEG) to evaluate the formation of serum and CSF protein coronas. LC-MS analysis revealed distinct protein compositions, with selective enrichment/depletion profiles. Following incubation with brain cells, serum and CSF coronas on PLGA particles showed enhanced associations with all cell types as compared to their corresponding corona on PLGA-PEG particles. CSF-derived protein coronas on PLGA nanoparticles, specifically, showed the greatest nanoparticle-cell interactions, with Pearson’s correlation analysis revealing that proteins associated with enhanced nanoparticle-cell interactions were exclusively enriched in this protein corona. This study demonstrates the importance of correct choice of physiologically relevant biological fluids, and its influence on the formation of the protein corona, subsequent nanoparticle-cell interactions.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Morshed,

Rennie,

Faria

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Nanoparticle Formulations for the Improvement of Symptomatic Treatments of Neurodegenerative Disorders

Boyton,

Rennie,

Collins‐Praino

et al. 2024

ChemNanoMat

View full text Add to dashboard Cite

Neuronanomedicine merges nanotechnology and neuroscience in the pursuit of engineering therapeutic interventions for neurological disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). While no nanoparticle‐based drug delivery systems (NDDSs) are yet approved for use for targeting the central nervous system, this review critically analyses the development of NDDSs for the improvement of currently approved therapeutics for the symptomatic treatment of AD and PD. It showcases how NDDSs can help therapeutic payloads overcome existing limitations, such as insufficient drug accumulation in the brain and limited effectiveness, by enhancing their pharmacokinetics, bioavailability, brain penetration and accumulation, and overall therapeutic efficacy through drug encapsulation, manipulation of nanoparticle properties, and nanoparticle surface functionalisation. However, we also draw attention to widespread issues in the field that impede progress, including the poor selection of in vitro models and the inadequate design of pre‐clinical in vivo studies. We further advocate for greater standardisation of study design and reporting requirements in the future, which would likely enhance outcomes and expedite the translation of neuronanomedicines.

show abstract

Synthesis and characterization of tannic acid–copper complex: A promising anticholinesterase drug

Ferreira,

Campelo,

Alves

et al. 2024

Polyhedron

View full text Add to dashboard Cite

Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation

Cited by 6 publications

References 190 publications

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Nanoparticle Formulations for the Improvement of Symptomatic Treatments of Neurodegenerative Disorders

Synthesis and characterization of tannic acid–copper complex: A promising anticholinesterase drug

Contact Info

Product

Resources

About